Insider Selling: Maze Therapeutics (NASDAQ:MAZE) Insider Sells $210,150.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $28.02, for a total value of $210,150.00. Following the transaction, the insider owned 26,250 shares of the company’s stock, valued at $735,525. This trade represents a 22.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Wednesday, April 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $25.37, for a total value of $190,275.00.

Maze Therapeutics Price Performance

Maze Therapeutics stock traded down $0.03 during mid-day trading on Wednesday, hitting $29.81. 1,090,902 shares of the company were exchanged, compared to its average volume of 718,935. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. The business has a fifty day moving average of $25.75 and a 200 day moving average of $35.80. Maze Therapeutics, Inc. has a 1-year low of $10.98 and a 1-year high of $53.65. The company has a market capitalization of $1.65 billion, a PE ratio of -11.78 and a beta of 2.26.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. As a group, sell-side analysts expect that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have weighed in on MAZE. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Wedbush lifted their target price on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, March 16th. Mizuho raised Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Finally, BTIG Research reaffirmed a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, March 25th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Maze Therapeutics currently has an average rating of “Buy” and a consensus price target of $66.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada increased its position in Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after acquiring an additional 363 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Maze Therapeutics during the fourth quarter worth approximately $39,000. Ameritas Investment Partners Inc. lifted its position in shares of Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Maze Therapeutics during the fourth quarter valued at approximately $43,000. Finally, Russell Investments Group Ltd. grew its stake in shares of Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares during the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.